Anti-Angiogenic Treatment in Metastatic Colorectal Cancer: Current Issues and Future Aims

(E-pub Ahead of Print)

Author(s): Martini Giulia, Troiani Teresa, Cardone Claudia, Vitiello Pietro Paolo, Ciardiello Davide, Morgillo Floriana, Ciardiello Fortunato, Martinelli Erika*.

Journal Name: Current Cancer Therapy Reviews

Become EABM
Become Reviewer


Blocking angiogenesis represents a fundamental process in Colorectal Cancer (CRC) treatment. VEGF (vascular endothelial growth factor) pathway is implicated in various processes that regulate tumor vascularization and proliferation. In the last years, great efforts have been made thanks to the discovery of targeted drugs that block VEGF and its receptors conferring a benefit in a variety of tumors, including CRC. To date, four drugs have been approved for the treatment of metastatic CRC (mCRC): bevacizumab, aflibercept, ramucirumab and regorafenib. Unfortunately, patients relapse due to the appearance of resistance. The VEGF family, its role in the angiogenesis and complex heterogeneity of mechanisms that escape tumor blockade are not completely understood and there is a lack of biomarkers of response to anti-angiogenic drugs. We describe the principal mechanisms of resistance to anti-VEGF therapy and discuss potential biomarkers to be investigated in the near future.

Keywords: Colorectal cancer, angiogenesis, resistance, VEGF, biomarkers, targeted therapy.

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1573394714666181119145327
Price: $95